Journal of Virology, May 2001, p. 4158-4164, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4158-4164.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
-Subunit
of Integrin
v
6 in Infection by Foot-and-Mouth Disease
Virus
Pirbright Laboratory, Institute for Animal Health, Pirbright, Surrey GU24 ONF, United Kingdom,1 and Lung Biology Center, Cardiovascular Research Institute, Department of Medicine, University of California, San Francisco, California 94143-08542
Received 17 November 2000/Accepted 9 February 2001
| |
ABSTRACT |
|---|
|
|
|---|
Field isolates of foot-and-mouth disease virus (FMDV) are believed
to use RGD-dependent integrins as cellular receptors in vivo. Using
SW480 cell transfectants, we have recently established that one such
integrin,
v
6, functions as a receptor for FMDV. This integrin was
shown to function as a receptor for virus attachment. However, it was
not known if the
v
6 receptor itself participated in the events
that follow virus binding to the host cell. In the present study, we
investigated the effects of various deletion mutations in the
6
cytoplasmic domain on infection. Our results show that although loss of
the
6 cytoplasmic domain has little effect on virus binding, this
domain is essential for infection, indicating a critical role in
postattachment events. The importance of endosomal acidification in
v
6-mediated infection was confirmed by experiments showing that
infection could be blocked by concanamycin A, a specific inhibitor of
the vacuolar ATPase.
| |
INTRODUCTION |
|---|
|
|
|---|
Foot-and-mouth disease virus (FMDV) is one of the most infectious animal pathogens known. It causes a vesicular disease of cloven-hoofed animals, which spreads by aerosol, sometimes over long distances. The primary site of infection in cattle is the epithelium of the pharynx (47). It can be assumed that the pathology of foot-and-mouth disease and its ability to spread reflect processes at the cellular level concerning the choice of surface receptor and mechanism of infection.
FMDV is the type species of the Aphthovirus genus within the family Picornaviridae. The small nonenveloped virion consists of an 8.5-kb strand of RNA within an icosahedral capsid formed from 60 copies each of four proteins (VP1 to VP4). The virus infects cells by attaching to integrin receptors through a long surface loop, the G-H loop, of VP1 (28, 30, 31, 34, 35). The sequence of this loop contains the conserved tripeptide, Arg-Gly-Asp (RGD), which is characteristic of the ligands of several members of the integrin family (27). Some FMDVs can use heparan sulfate proteoglycans as alternative receptors, but this ability appears to be an adaptation to growth in cell culture, and there is no convincing evidence of a role for heparan sulfate in cell entry by field strains of FMDV (22, 29, 40, 46).
Integrins are a family of cell surface glycoproteins which function in
a variety of adhesion and signaling phenomena (6, 16, 24,
27). Each molecule is composed of two large, type 1 transmembrane polypeptides,
and
, which, in most cases, have short cytoplasmic domains. To date, two species of RGD-binding integrin,
v
3 and
v
6, have been reported to mediate FMDV
infection in cell culture (5, 31). Of the two, only
v
6 is expressed in epithelial tissues, and this species is
currently the most plausible receptor in the animal host
(31). We recently reported that this integrin serves as an
attachment receptor for FMDV, but we have no information on what part,
if any, this integrin plays in subsequent events during infection
(31). The work described in this paper was undertaken to
elucidate the part played by
v
6 in the events that follow virus
attachment to the host cell.
For an infecting virion, the entry pathway culminates in the uncoating
of the RNA genome and its transfer across a membrane into the cytosol.
These processes are poorly understood for nonenveloped viruses,
although it is clear that picornaviruses have evolved a variety of
strategies for gaining entry to cells. For enteroviruses and the ICAM-1
receptor group of rhinoviruses, binding to the receptor triggers a
profound structural transformation to the so-called altered or A
particle, and this change is thought to be a prerequisite for release
of the RNA (3, 11, 18, 21, 26, 42). For other
picornaviruses, such as coxsackievirus A21 and certain enteroviruses
that bind decay-accelerating factor, virus binding to the primary
attachment receptor does not lead to formation of A-particles, instead
A-particle formation is initiated by virus binding to a secondary or
coreceptor (42, 43, 48). For FMDV, by contrast, there is
no evidence for A-particle formation. Such a transformation would not
be needed by a virus, like FMDV, that dissociates into pentamers, RNA,
and VP4 at pH values just below neutrality (10, 14, 20).
Instead, the virus is thought to enter endosomes, leading to capsid
uncoating in the acidic environment of this compartment. Some evidence
for this mechanism comes from the inhibitory effect of monensin
(4) which raises endosomal pH. Capsid dissociation by some
picornaviruses, such as the minor receptor group rhinoviruses, appears
to involve aspects of both the enterovirus and FMDV pathways, since
A-particle formation is triggered not by virus binding to its receptor
but by acidic pH following virus uptake into endosomes
(44). FMDV can thus be considered a simple model for
endocytic cell entry by a nonenveloped virus. In the present study, we
set out to determine what role
v
6 plays during the postattachment
phases of infection by FMDV by investigating the effects of deletions
in the cytoplasmic domain of the
6 subunit. We chose this target
because many of the functional properties of integrins, including the
regulation of binding affinity, signal transduction, and
integrin-mediated uptake of ligands, are dependent on the integrity of
the cytoplasmic domain of the
-subunit (6, 8, 16, 24, 27, 41,
50, 55). Our data show that although the
6 cytoplasmic domain
is not required for virus binding, this domain is essential for
infection, indicating a critical role in postattachment events. In
addition, we show that
v
6-mediated infection is dependent on
active endosomal acidification, implying that infection mediated by
v
6 most likely proceeds through endosomes. Together, the results
of these experiments are consistent with FMDV entering cells through
receptor-mediated endocytosis and are discussed in relation to the
normal cellular functions of the integrin
-subunit cytoplasmic domain.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cells and viruses.
BHK cells were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum
(FCS), 20 mM glutamine, penicillin (100 Système International
d'Unités [SI] units/ml), and streptomycin (100 µg/ml).
Construction of SW480 cell transfectants expressing wild-type
v
6
or
v
6 with deletions in the cytoplasmic domain of the
6-subunit has been described (1, 13, 38, 54).
Transfectants were cultivated in DMEM supplemented with 10% FCS, 20 mM
glutamine, penicillin (100 SI units/ml), streptomycin (100 µg/ml),
and 1 mg of Geneticin (Life Technologies) per ml. Stocks of the
non-heparin-binding FMDV strains O1Kcad2 and SAT-3 Zim4/81
(SAT-3) were propagated in primary bovine thyroid cells or BHK cells,
respectively. The multiplicity of infection (MOI) was based on the
virus titer on BHK cells. FMDV purification was done as described
previously (15).
Antibodies, peptides, and reagents.
The sequence of the RGD
peptide used in these studies was derived from the GH loop of VP1 of
type O FMDV (142-VPNLRGDLQVLA-153). The antiintegrin antibodies used in
these studies were P1F6 (anti-
v
5), E7P6 (anti-
v
6)
(54), and 10D5 (anti-
v
6) (25) all from Chemicon. The anti-FMDV monoclonal antibodies (MAbs) B2 and D9 (36), which recognize type O virus, were purified using
protein A (Pierce) according to the manufacturer's instructions.
Concanamycin A was purchased from FLUKA and stored at
20°C as a 10 mM stock in dimethyl sulfoxide (DMSO).
Infectious center assay. Cells were harvested using 20 mM EDTA in phosphate-buffered saline (PBS) (pH 7.5), washed, and resuspended in cell culture media. One million cells were infected with SAT-3 (MOI = 1 PFU/cell) or with O1Kcad2 (MOI = 0.5) in 100 µl of DMEM supplemented with 1% FCS at 37°C for 1 h with continuous rotation. Following infection, virus that remained outside the cells was inactivated by the addition of 1 ml of 0.1 M citric acid buffer (pH 5.2) for 1 min. The cells were washed with PBS (pH 7.5) containing 2 mM CaCl2 and 1 mM MgCl2 and resuspended in 300 µl of the same buffer supplemented with 0.5% FCS. Dilutions of the infected cells (100 µl) were layered onto subconfluent monolayers of BHK cells as previously described (31), and the monolayers were incubated at 37°C for 40 to 48 h. Infectious centers were visualized as plaques by staining with methylene blue and 4% formaldehyde in PBS (pH 7.5). When antiintegrin antibodies were used to block infection, these reagents were added to the cells for 30 min at room temperature prior to infection.
Concanamycin A experiments. (i) Pretreatment of cells.
Confluent monolayers of SW480 cells expressing wild-type
v
6 in
35-mm-diameter dishes were treated with concanamycin A or DMSO (mock
treatment) in DMEM with 5% FCS for 30 min at 37°C. The drug was
removed, and the cells were infected with SAT-3 (MOI = 2 PFU/cell)
for 1 h at 37°C in the presence of fresh drug. Virus that
remained outside the cells was acid inactivated as described above.
Cell monolayers were washed with PBS (pH 7.5) and incubated in DMEM
with 5% FCS at 37°C. At 12 h postinfection, the titer of
infectious virus in the cell supernatant was determined by plaque assay
on BHK cells as previously described (31).
(ii) Treatment with concanamycin A postinfection. To confirm that concanamycin A was not acting on a postentry step of virus replication, cell monolayers were treated with the drug after infection. Cell monolayers were infected, and virus that remained outside the cells was acid inactivated as described above. At 1 h postinfection, the culture medium was replaced by fresh medium containing either concanamycin A or DMSO, and incubation at 37°C continued for 1.5 h. The cell monolayers were then washed and incubated in fresh cell culture media at 37°C. At 12 h postinfection, the virus titer in the cell supernatant was determined by plaque assay as described above.
Flow cytometry analysis. (i) Integrin expression. Cells were harvested using EDTA as described above, washed, and resuspended at ~107 cells per ml in buffer A (cold PBS [pH 7.5], 2 mM CaCl2, 1 mM MgCl2, 1% goat serum, 3% bovine serum albumin, 0.1% sodium azide). All subsequent steps were performed on ice. Cells (30 µl) were incubated with primary antibodies (10 µg/ml) for 30 min. The cells were washed and incubated with a goat anti-mouse immunoglobulin G IgG-biotin conjugate for 30 min. Following another washing step, the cells were incubated with a streptavadin-R-phycoerythrin conjugate (Southern Biotechnology Associates). The cells were then washed twice and resuspended in 1% paraformaldehyde in PBS. Fluorescence staining was analyzed by flow cytometry using a FACSCalibur (Becton Dickinson) counting 10,000 cells per sample. Background fluorescence was determined by omitting the primary antibody from the assay.
(ii) Virus binding assay. Cells were prepared in buffer A as described above and incubated with O1Kcad2 (10 µg/ml) for 30 min on ice. The cells were washed twice and incubated sequentially with the anti-FMDV MAb D9 (10 µg/ml), followed by a goat anti-mouse IgG2a-specific R-phycoerythrin conjugate. Background fluorescence was determined by omitting either FMDV or MAb D9 from the assay. Both control conditions gave near-identical results.
(iii) Competition experiments.
The anti-
v
6 MAb 10D5
(IgG2a) or peptides were added to the cells for 30 min before the
addition of virus for a further 30 min. The cells were then washed, and
cell-bound virus was detected using an anti-FMDV MAb, B2 (IgG1),
followed by a goat anti-mouse IgG1-specific R-phycoerythrin conjugate.
| |
RESULTS |
|---|
|
|
|---|
The
6 cytoplasmic domain is not required for FMDV binding.
Previously, we showed that the RGD-dependent integrin
v
6
functions as a receptor for FMDV when expressed on transfected SW480
cells (SW480-
v
6) (31). To determine whether the
cytoplasmic domain of the
6 subunit is required for FMDV infection,
we used a series of stably transfected cell lines expressing five
different deletion mutations in the cytoplasmic domain of the
6
subunit (SW480-T1 to SW480-T5 [Fig.
1]). These cells have been reported to
show similar
v
6 expression at the cell surface (13).
Initially, we confirmed this observation by flow cytometry using a MAb
specific for the extracellular domain of
v
6. We found that on
transfectants SW480-T2 and SW480-T3,
v
6 expression was virtually
identical to that of the wild-type integrin expressed on
SW480-
v
6, whereas integrin expression on transfectants SW480-T1,
SW480-T4, and SW480-T5 was slightly reduced (see Fig. 4).
|
v
6 (SW480-
v
6) but not to the
mock-transfected cells, thus confirming our previous observation
(31). In addition, Fig. 2 shows that cells expressing the
mutant integrin also bind FMDV. However, a small proportion of the
cells in the SW480-T5 clone did not appear to bind virus. From the
experiments shown below (see Fig. 4), we estimate the proportion of
nonbinding cells to be 10 to 15%. To verify that virus binding to the
cells was mediated by an authentic RGD-dependent interaction with
v
6, we performed competition experiments using the anti-
v
6
MAb 10D5 and an RGD-containing peptide. Previously we have shown that
these reagents inhibit FMDV binding to
v
6, whereas a functional
blocking antibody to
v
5 or the RGE version of the peptide have no
effect on virus binding (31). Pretreatment of cells with
MAb 10D5 or the RGD peptide inhibited virus binding, confirming that as
for cells expressing wild-type integrin,
v
6 serves as the major
receptor for FMDV attachment on the cells expressing mutated integrins (Fig. 3). Furthermore, these results show
that the
6 cytoplasmic domain is not required for FMDV binding to
v
6.
|
|
v
6
expression was observed with the transfected cells with the exception
of SW480-T2, as these cells supported less virus binding relative to
the level of integrin expression (Fig.
4).
v
6 receptors expressed on
SW480-T2 have been shown to be deficient in binding to
latency-associated protein of TGF
1, the natural ligand for
v
6
(38). Taken together, these data indicate that the
majority of the
v
6 on SW480-T2 is expressed in a conformation
that is unable to bind RGD ligands.
|
The
6 cytoplasmic domain is essential for
v
6-mediated
infection by FMDV.
The above data show that the cytoplasmic domain
of the
6-subunit is not required for FMDV binding. We next sought to
determine whether this domain is required for
v
6-mediated
infection. Truncations in the cytoplasmic domain of the
6 subunit
have been shown to change the surface distribution of
v
6 from
sites of tight contact with the underlying substratum (focal contacts)
and that free in the plasma membrane (13). Since the
amount of
v
6 localized to focal contacts could potentially
influence the number of integrin receptors available for virus binding
and therefore infection, we performed infectivity studies using an
infectious center assay with dispersed cells in suspension, thereby
permitting a direct comparison to be made between virus binding and infection.
6 cytoplasmic domain are not essential for infection.
Consistent with the observation that virus binding to SW480-T3 and
SW480-T4 is inhibited by MAb 10D5, we found that infection of these
cells was also inhibited (>98%) by pretreatment of cells with this
antibody (100 µg/ml), whereas the anti-
v
5 MAb P1F6 had no
effect on infection (data not shown). By contrast, virus binding to
SW480-T1, SW480-T2, and SW480-T5 resulted in little or no infection
(Table 1 and Fig. 4). The small number of infectious centers generated
with SW480-T5 was also completely inhibited by MAb 10D5 (data not
shown). Taken together, the results of these experiments show that
although the cytoplasmic domain of
6 subunit is not required for
FMDV binding, this domain has a critical role in regulating
postattachment steps in
v
6-dependent infection.
|
Infection of
v
6-expressing cells requires active endosomal
acidification.
Previous studies have demonstrated that infection
of BHK cells by FMDV is inhibited by treatment of the cells with the
ionophore monensin, one effect of which is to raise the pH within
endosomes, implying that infection proceeds through this compartment
(4). To determine whether it is also true of
v
6-mediated infection, we investigated the effect on infection of
concanamycin A, a specific inhibitor of the vacuolar proton-ATPase
(19). Preliminary studies, using one-step growth curve
analysis, showed that pretreatment of cells with concanamycin A reduced
the virus titer in cell supernatants compared to that of mock-treated
controls over time in a concentration-dependent manner (data not
shown). Figure 5 shows that treatment of
cells with concanamycin A (10 µM) prior to infection reduced the
virus titer in the cell supernatant compared to that of mock-treated controls. Treatment of cells with concanamycin A at 1 h after infection had a minimal effect on the virus titer (Fig. 5) showing that
the drug was not inhibiting a postentry step necessary for virus
replication. These data show that active endosomal acidification is
required for an early event in
v
6-mediated infection and imply
that infection proceeds through endosomes.
|
| |
DISCUSSION |
|---|
|
|
|---|
Entry of picornavirus into host cells is a complex process
initiated by virus binding to a specific cell surface receptor. Although receptors for FMDV have been identified, there is little information on the precise mechanisms by which these receptors promote
entry. Recently, we showed that the RGD-dependent integrin
v
6
serves as a receptor for FMDV attachment and that virus binding to the
integrin results in an increased rate of cell entry (31). In the present study, we have focused on the role of the
6
cytoplasmic domain in FMDV infection. Our results show that complete
truncation of the
6 cytoplasmic domain resulted in receptors that
although expressed on the cell surface and able to bind FMDV, were
defective in mediating infection.
The obvious question that arises from these observations is what is the
role of the
6 cytoplasmic domain in infection. The need for
6
cytoplasmic domains implies that
v
6 does not merely serve to pass
virus onto a second receptor for internalization but plays an active
role in events subsequent to attachment. The sensitivity of infection
to concanamycin A confirms that
v
6-mediated infection involves an
acidification step and is consistent with virus entry proceeding
through endosomes. This observation suggests that the regions deleted
from the
v
6 expressed on SW480-T1, SW480-T2, and SW480-T5 may
contain important signals for virus localization to endosomes.
Interestingly, all of these receptors lack the
6 cytoplasmic domain
NPXY motif (Fig. 1). This motif is known to function as a signal that
directs various membrane proteins into clathrin-coated vesicles
(12). However, the role of the
-subunit NPXY sequence
in integrin endocytosis is not well defined (50, 51, 55),
and further experimentation will be necessary to more precisely define
the role of this motif in FMDV infection.
While infection by FMDV depended completely on the presence of the
6
cytoplasmic domain, smaller inhibitory effects were also seen with
6
chains C terminally truncated in such a way as to leave the NPXY motif
intact. Loss of the C-terminal 11 residues, for example, caused
approximately 80% reduction in infection (Fig. 4, mutant T4).
Interestingly, a similar observation was reported for the T4 cell line
by Agrez et al. (2) when studying infection by another
picornavirus, coxsackievirus B1. The reason for this impairment is
unclear, however, as we found that deleting a further 7 residues (T3)
partially restored receptor function to
v
6.
The
6 cytoplasmic domain could also be needed to complete the final
uncoating step in which the viral genome is translocated into the
cytosol. Such a requirement has recently been demonstrated for
v
5-mediated infection by adenovirus (52), but it
seems less likely in the FMDV system, given that FMDV has been shown to
infect cells through at least three integrin-independent mechanisms (29, 35, 45), thereby implying that the function of
membrane permeabilization is an inherent property of the virus and not the receptor.
Many of the intracellular signaling pathways activated by integrins are
dependent on the
-subunit cytoplasmic domain, which points to a
further possible function of the
6 cytoplasmic domain in
facilitating virus entry. For example, signal transduction through
v
6 could be required to activate a coreceptor necessary for virus
internalization. Signal transduction through integrins is known to
regulate the ligand-binding affinity of other integrin species
expressed on the same cell by a mechanism termed integrin cross-talk
(7). SW480 cells normally express two RGD-dependent integrins,
v
5 and
5
1, and either of these integrins could conceivably be activated following virus binding to
v
6. However, as we showed previously that neither of these integrins appear to be
involved in infection of SW480 cells expressing wild-type
v
6,
this mechanism may be discounted (31). Although we
consider it unlikely, we cannot rule out the possibility that signaling through the
6 cytoplasmic domain is necessary for activation of a
nonintegrin coreceptor. Alternatively, virus binding to
v
6 could
initiate intracellular signaling pathways that are advantageous for a
postentry step in virus replication and/or assembly. However, since
mock-transfected SW480 cells in the absence of
v
6 are permissive
for a heparin-binding strain of FMDV (31), such a role for
v
6 in infection would similarly appear unlikely. However, on the
basis of our data, we cannot rule out the possibility that signaling
through
v
6 may be required to promote infection by FMDV by
stimulating endocytosis of
v
6 itself. For example, endosomal uptake of the integrin
v
5 has been shown to be stimulated by ligand binding (37), and more recently,
v
5-mediated
endocytosis of adenovirus has been shown to require activation of
phosphoinositide-3-OH kinase (PI3K), an event dependent on the
5
cytoplasmic domain (33). Using one-step growth curve
analysis, we have observed that treatment of cells expressing wild-type
v
6 with wortmannin (50 to 200 nM), a specific inhibitor of PI3K,
did not affect virus replication, suggesting that PI3K activity is not
required for
v
6-dependent infection by FMDV (data not shown).
Our findings contrast with those obtained with some other picornaviruses, namely, poliovirus, coxsackievirus B3, and human rhinovirus type 14 (HRV-14), which show that the single cytoplasmic domain of their receptors are not needed for infection (32, 49, 53). Since such modifications might be expected to prevent receptor uptake into endosomes, these differences tend to support the view that for these latter viruses infection is not dependent on classical receptor-mediated endocytosis or at least not totally dependent on that route. For poliovirus, this view is supported by the observation that infection is not dependent on dynamic-mediated endocytic pathways (17). However, it should be noted that the same study (17) concluded the opposite for HRV-14, i.e., infection requires dynamin-mediated endocytosis to be functional. An additional difference between these viruses and FMDV is that unlike FMDV, they form A-particles on receptor binding and for poliovirus and HRV-14, conversion to A-particles has been shown to occur on binding soluble receptors which lack cytoplasmic domains (32, 49).
While this study was in progress, Neff and Baxt (39)
reported findings with
v
3-expressing cells which would also lead to the opposite conclusion, namely, that infection of COS cells by FMDV
does not require the cytoplasmic domain of either the
- or
-subunit. However, the role played by
v
3 in this system remains unclear, since although this integrin was shown to be required
for infection, studies with
v
3-expressing cells have never
clearly established that FMDV binds to this integrin (5, 39).
While the precise mechanisms involved in
v
6-mediated infection
require further investigation, the finding reported herein helps in the
understanding of postattachment events in FMDV infection.
| |
ACKNOWLEDGMENTS |
|---|
Peptides were synthesized at the peptide synthesis facility at the Oxford Centre for Molecular Science, New Chemistry Laboratory, Oxford.
L.C.M. was a recipient of an IAH Ph.D. studentship. This work was supported in part by MAFF.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Pirbright Laboratory, Institute for Animal Health, Ash Rd., Pirbright, Surrey GU24 ONF, United Kingdom. Phone: 44-1483-232441. Fax: 44-1483-237161. E-mail: terry.jackson{at}bbsrc.ac.uk.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Agrez, M.,
A. Chen,
R. I. Cone,
R. Pytela, and D. Sheppard.
1994.
The v 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the 6 cytoplasmic domain.
J. Cell Biol.
127:545-556.
|
| 2. |
Agrez, M.,
D. R. Shafren,
X. Gu,
K. Cox,
D. Sheppard, and R. D. Barry.
1997.
Integrin v 6 enhances coxsackievirus B1 lytic infection of human colon carcinoma cells.
Virology
239:71-77[CrossRef][Medline].
|
| 3. |
Arita, M.,
S. Koike,
J. Aoki,
H. Horie, and A. Nomoto.
1998.
Interactions of poliovirus with its purified receptor and conformational alterations in the virion.
J. Virol.
72:3578-3586 |
| 4. | Baxt, B. 1987. Effect of lysosomotropic compounds on early events in foot-and-mouth disease virus replication. Virus Res. 7:257-271[CrossRef][Medline]. |
| 5. |
Berinstein, A.,
M. Roivainen,
T. Hovi,
P. W. Mason, and B. Baxt.
1995.
Antibodies to the vitronectin receptor (integrin v 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells.
J. Virol.
69:2664-2666[Abstract].
|
| 6. | Bianchi, E., S. Denti, A. Granata, G. Bossi, J. Geginat, A. Villa, L. Rogge, and R. Pardi. 2000. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature 404:617-621[CrossRef][Medline]. |
| 7. |
Blystone, S. D.,
S. E. Slater,
M. P. Williams,
M. T. Crow, and E. Brown.
1999.
A molecular mechanism of integrin crosstalk: v 3 suppression of calcium/calmodulin-dependent protein kinase II regulates 5 1 function.
J. Cell Biol.
145:889-897 |
| 8. |
Blystone, S. D.,
M. P. Williams,
S. E. Slater, and E. J. Brown.
1997.
Requirement of integrin 3 tyrosine 747 for 3 tyrosine phosphorylation and regulation of v 3 avidity.
J. Biol. Chem.
272:28757-28761 |
| 9. | Bullough, P. A., F. M. Hughson, J. J. Skehel, and D. Wiley. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43[CrossRef][Medline]. |
| 10. |
Burroughs, J. N.,
D. J. Rowlands,
D. V. Sanger,
P. Talbot, and F. Brown.
1971.
Further evidence for multiple proteins in the foot-and-mouth disease virus particle.
J. Gen. Virol.
13:73-84 |
| 11. |
Casasnovas, J. M., and T. A. Springer.
1994.
Pathways of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released.
J. Virol.
68:5882-5889 |
| 12. |
Chen, W. J.,
J. L. Goldstein, and M. S. Brown.
1990.
NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor.
J. Biol. Chem.
265:3116-3123 |
| 13. |
Cone, R. I.,
A. Weinacker,
A. Chen, and D. Sheppard.
1994.
Effects of subunit cytoplasmic domain deletions on the recruitment of the integrin v 6 to focal contacts.
Cell Adhes. Commun.
2:101-113[Medline].
|
| 14. | Curry, S., C. C. Abrams, E. Fry, J. C. Crowther, G. J. Belsham, D. I. Stuart, and A. M. King. 1995. Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids. J. Virol. 69:430-438[Abstract]. |
| 15. | Curry, S., E. Fry, W. E. Blakemore, R. Abu-Ghazaleh, T. Jackson, A. King, S. Lea, J. Newman, D. Rowlands, and D. Stuart. 1996. Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity. Structure 4:135-145[Medline]. |
| 16. | Dedhar, S., and G. E. Hannigan. 1996. Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Curr. Opin. Cell Biol. 8:657-669[CrossRef][Medline]. |
| 17. | DeTulleo, L., and T. Kirchhausen. 1998. The clathrin endocytic pathway in viral infection. EMBO J. 17:4585-4593[CrossRef][Medline]. |
| 18. | Dove, A. W., and V. R. Racaniello. 1997. Cold-adapted poliovirus mutants bypass a postentry replication block. J. Virol. 71:4728-4735[Abstract]. |
| 19. | Drose, S., K. U. Bindseil, E. J. Bowman, A. Siebers, A. Zeeck, and K. Altendorf. 1993. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosine triphosphatases. Biochemistry 32:3902-3906[CrossRef][Medline]. |
| 20. |
Ellard, F. M.,
J. Drew,
W. E. Blakemore,
D. I. Stuart, and A. M. Q. King.
1999.
Evidence for the role of His-142 of protein 1C in the acid-induced disassembly of foot-and-mouth disease virus capsids.
J. Gen. Virol.
80:1911-1918 |
| 21. |
Fricks, C. E., and J. M. Hogle.
1990.
Cell-induced conformational changes in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.
J. Virol.
64:1934-1945 |
| 22. | Fry, E., S. M. Lea, T. Jackson, J. W. I. Newman, F. M. Ellard, W. E. Blakemore, R. Abu-Ghazaleh, A. Samuel, A. M. Q. King, and D. I. Stuart. 1999. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 18:543-554[CrossRef][Medline]. |
| 23. | Guinea, R., and L. Carrasco. 1995. Requirement for vacuolar proton- ATPase activity during entry of influenza virus into cells. J. Virol. 69:2306-2312[Abstract]. |
| 24. | Howe, A., A. E. Aplin, S. K. Alahari, and R. Juliano. 1998. Integrin signalling and cell growth control. Curr. Opin. Cell Biol. 10:220-231[CrossRef][Medline]. |
| 25. |
Huang, X.,
J. F. Wu,
S. Spong, and D. Sheppard.
1998.
The integrin v 6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin.
J. Cell Sci.
111:2189-2195[Abstract].
|
| 26. |
Huang, Y.,
J. Hogle, and M. Chow.
2000.
Is the 135S poliovirus particle an intermediate during cell entry?
J. Virol.
74:8757-8761 |
| 27. | Hynes, R. O. 1992. Integrins: versatility, modulation, and signalling in cell adhesion. Cell 69:11-25[CrossRef][Medline]. |
| 28. |
Jackson, T.,
A. Sharma,
R. Abu-Ghazaleh,
W. E. Blakemore,
F. M. Ellard,
D. L. Simmons,
J. W. I. Newman,
D. I. Stuart, and A. M. Q. King.
1997.
Arginine-glycine-aspartic acid-specific binding by foot-and-mouth disease virus to the purified integrin v 3 in vitro.
J. Virol.
71:8357-8361[Abstract].
|
| 29. |
Jackson, T.,
F. M. Ellard,
R. Abu-Ghazaleh,
S. M. Brookes,
W. E. Blakemore,
A. H. Corteyn,
D. I. Stuart,
J. W. I. Newman, and A. M. Q. King.
1996.
Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate.
J. Virol.
70:5282-5287 |
| 30. |
Jackson, T.,
W. E. Blakemore,
J. W. I. Newman,
N. J. Knowles,
A. P. Mould,
M. J. Humphries, and A. M. Q. King.
2000.
Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin 5 1: influence of the leucine residue within the RGDL motif on selectivity of integrin binding.
J. Gen. Virol.
81:51383-51391.
|
| 31. |
Jackson, T.,
D. Sheppard,
M. Denyer,
W. E. Blakemore, and A. M. Q. King.
2000.
The epithelial integrin v 6 is a receptor for foot-and-mouth disease.
J. Virol.
74:4949-4956 |
| 32. |
Koike, S.,
I. Ise, and A. Nomoto.
1991.
Functional domains of the poliovirus receptor.
Proc. Natl. Acad. Sci. USA
88:4104-4108 |
| 33. |
Li, E.,
D. Stupack,
R. Klemke,
D. A. Cheresh, and G. R. Nemerow.
1998.
Adenovirus endocytosis via v integrins requires phosphoinositide-3-OH kinase.
J. Virol.
72:2055-2061 |
| 34. | Logan, D., R. Abu-Ghazaleh, W. E. Blakemore, S. Curry, T. Jackson, A. King, S. Lea, R. Lewis, J. W. I. Newman, N. Parry, D. Rowlands, D. Stuart, and E. Fry. 1993. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362:566-568[CrossRef][Medline]. |
| 35. |
Mason, P. W.,
E. Reider, and B. Baxt.
1994.
RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway.
Proc. Natl. Acad. Sci. USA
91:1932-1936 |
| 36. |
McCahon, D.,
J. R. Crowther,
G. J. Belsham,
J. D. A. Kitson,
M. Duchesne,
P. Have,
R. H. Meloen,
D. O. Morga, and F. de Simone.
1989.
Evidence for at least 4 antigenic sites on type foot-and-mouth disease virus involved in neutralization: identification by single and multiple monoclonal antibody-resistant mutants.
J. Gen. Virol.
70:639-645 |
| 37. |
Memmo, L. M., and P. McKeown-Longo.
1998.
The v 5 integrin functions as an endocytic receptor for vitronectin.
J. Cell Sci.
111:425-433[Abstract].
|
| 38. |
Munger, J. S.,
X. Huang,
H. Kawakatsu,
M. D. J. Griffiths,
S. L. Dalton,
J. Wu,
J. F. Pittet,
N. Kaminski,
C. Garat,
M. A. Matthay,
D. B. Rifkin, and D. Sheppard.
1999.
The integrin v 6 binds and activates latent TGF 1: a mechanism for regulating pulmonary inflammation and fibrosis.
Cell
96:319-328[CrossRef][Medline].
|
| 39. |
Neff, S., and B. Baxt.
2001.
The ability of integrin v 3 to function as a receptor for foot-and-mouth disease virus is not dependent on the presence of complete subunit cytoplasmic domains.
J. Virol.
75:527-532 |
| 40. |
Neff, S.,
D. Sa-Carvalho,
E. Rieder,
P. W. Mason,
S. D. Blystone,
E. J. Brown, and B. Baxt.
1998.
Foot-and-mouth disease virus virulent for cattle utilizes the integrin v 3 as its receptor.
J. Virol.
72:3587-3594 |
| 41. |
O'Toole, T. E.,
J. Ylanne, and B. M. Culley.
1995.
Regulation of integrin affinity states through an NPXY motif in the b subunit cytoplasmic domain.
J. Biol. Chem.
270:8553-8558 |
| 42. | Pasch, A., J. Kupper, A. Wolde, R. Kandolf, and H. Selinka. 1999. Comparative analysis of virus-host cell interactions of haemagglutinating and non-haemagglutinating strains of coxsackievirus B3. J. Gen. Virol. 80:53153-53158. |
| 43. | Powell, R. M., T. Ward, D. J. Evans, and J. W. Almond. 1997. Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation. J. Virol. 71:9306-9312[Abstract]. |
| 44. |
Prchla, E.,
E. Kuechler,
D. Blass, and R. Fuchs.
1994.
Uncoating of human rhinovirus serotype 2 from late endosomes.
J. Virol.
68:3713-3723 |
| 45. |
Reider, E.,
A. Berinstein,
B. Baxt,
A. Kang, and P. W. Mason.
1996.
Propagation of an attenuated virus by design: engineering a novel receptor for noninfectious foot-and-mouth disease.
Proc. Natl. Acad. Sci. USA
93:10428-10433 |
| 46. | Sa-Carvalho, D., E. Rieder, B. Baxt, R. Rodarte, A. Tanuri, and P. W. Mason. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115-5123[Abstract]. |
| 47. | Salt, J. S. 1998. Persistent infection with foot-and-mouth disease virus. Top. Trop. Virol. 1:77-129. |
| 48. | Shafren, D. R., D. J. Dorahy, R. A. Ingham, G. F. Burns, and R. Barry. 1997. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 71:4736-4743[Abstract]. |
| 49. | Staunton, D. E., A. Gaur, P. Chan, and T. Springer. 1992. Internalization of a major group human rhinovirus does not require cytoplasmic or transmembrane domains of ICAM-1. J. Immunol. 148:3271-3274[Abstract]. |
| 50. |
Van Nhieu, G. T.,
E. S. Krukonis,
A. A. Reszka,
A. F. Horwitz, and R. R. Isberg.
1996.
Mutations in the cytoplasmic domain of the integrin 1 chain indicate a role for endocytosis factors in bacterial internalisation.
J. Biol. Chem.
271:7665-7672 |
| 51. |
Vignould, L.,
Y. Usson,
F. Balzac,
G. Tarone, and M. R. Block.
1994.
Internalization of the 5 1 integrin does not depend on "NPXY" signals. 1994.
Biochem. Biophys. Res. Commun.
2:603-611.
|
| 52. |
Wang, K.,
T. Guan,
D. A. Cheresh, and G. R. Nemerow.
2000.
Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin 5.
J. Virol.
74:2731-2739 |
| 53. |
Wang, X., and J. M. Bergelson.
1999.
Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection.
J. Virol.
73:2559-2562 |
| 54. |
Weinacker, A.,
A. Chen,
M. Agrez,
R. I. Cone,
S. Nishimura,
E. Wayner,
R. Pytela, and D. Sheppard.
1994.
Role of the integrin v 6 in cell attachment to fibronectin.
J. Biol. Chem.
269:6940-6948 |
| 55. |
Ylänne, J.,
J. Huuskonen,
T. E. O'Toole,
M. H. Ginsberg,
I. Virtanen, and C. G. Gahmberg.
1995.
Mutation of the cytoplasmic domain of the integrin 3 subunit. Differential effects on cell spreading, recruitment to adhesion plaques, endocytosis and phagocytosis.
J. Biol. Chem.
270:9550-9557 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. |
|---|